Tildrakizumab Holds Its Effect for 52 Weeks in Japanese Psoriasis Patients
Tildrakizumab sustained its benefit over 52 weeks in Japanese psoriasis patients in real-world care, adding durability evidence for the IL-23 inhibitor beyond trial settings.
Topic
Tildrakizumab
Topic
Tildrakizumab
Tildrakizumab Delivers Long-Term Control in Hard-to-Treat Psoriasis Areas
AJMC reports tildrakizumab sustained long-term psoriasis control in hard-to-treat areas such as scalp, palms and soles, strengthe…